4basebio (LON:4BB) Shares Up 4.8% – Here’s What Happened

Shares of 4basebio PLC (LON:4BB) rose 4.8% on Wednesday . The stock traded as high as GBX 496.80 and last traded at GBX 496.80. Approximately 242 shares changed hands during trading, a decline of 85% from the average daily volume of 1,596 shares. The stock had previously closed at GBX 474.

4basebio Price Performance

The company’s 50-day moving average is GBX 541.52 and its 200-day moving average is GBX 645.70. The firm has a market capitalization of £76.93 million, a price-to-earnings ratio of -5.02 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.

Insiders Place Their Bets

In related news, insider Amy Walker purchased 2,650 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were bought at an average price of GBX 586 per share, for a total transaction of £15,529. Also, insider Heikki Lanckriet acquired 3,000 shares of the stock in a transaction dated Tuesday, February 10th. The shares were bought at an average cost of GBX 576 per share, with a total value of £17,280. Insiders have purchased a total of 6,650 shares of company stock valued at $3,865,900 over the last quarter. Company insiders own 12.07% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.